News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
519,765 Results
Type
Article (44339)
Company Profile (135)
Press Release (475291)
Section
Business (144744)
Career Advice (2387)
Deals (27891)
Drug Delivery (113)
Drug Development (67822)
Employer Resources (148)
FDA (15561)
Job Trends (11927)
News (263270)
Policy (29565)
Tag
Academia (2282)
Alliances (35806)
Alzheimer's disease (1313)
Approvals (15492)
Artificial intelligence (134)
Bankruptcy (300)
Best Places to Work (9152)
Breast cancer (177)
Cancer (1305)
Cardiovascular disease (111)
Career advice (1993)
CAR-T (95)
Cell therapy (276)
Clinical research (54147)
Collaboration (415)
Compensation (263)
COVID-19 (2556)
C-suite (101)
Data (1284)
Diabetes (176)
Diagnostics (5113)
Drug pricing (104)
Earnings (57204)
Employer resources (136)
Events (75155)
Executive appointments (347)
FDA (16239)
Funding (355)
Gene therapy (204)
GLP-1 (670)
Government (3802)
Healthcare (14719)
Infectious disease (2651)
Inflammatory bowel disease (105)
Interviews (445)
IPO (13839)
Job creations (3153)
Job search strategy (1661)
Layoffs (456)
Legal (6911)
Lung cancer (193)
Lymphoma (98)
Manufacturing (200)
Medical device (11084)
Medtech (11087)
Mergers & acquisitions (14205)
Metabolic disorders (499)
Neuroscience (1632)
NextGen Class of 2024 (4970)
Non-profit (3158)
Northern California (1562)
Obesity (291)
Opinion (193)
Patents (120)
People (41972)
Phase I (16169)
Phase II (23437)
Phase III (19284)
Pipeline (512)
Postmarket research (2202)
Preclinical (6536)
Radiopharmaceuticals (202)
Rare diseases (268)
Real estate (4247)
Regulatory (20363)
Research institute (2050)
Resumes & cover letters (401)
Southern California (1308)
Startups (2735)
United States (13376)
Vaccines (634)
Weight loss (231)
Date
Today (2)
Last 7 days (236)
Last 30 days (2012)
Last 365 days (31396)
2024 (31339)
2023 (34982)
2022 (45057)
2021 (48498)
2020 (45512)
2019 (36210)
2018 (27397)
2017 (27804)
2016 (25804)
2015 (27973)
2014 (21774)
2013 (17791)
2012 (18963)
2011 (19382)
2010 (17504)
Location
Africa (667)
Arizona (140)
Asia (30630)
Australia (5365)
California (3419)
Canada (1089)
China (237)
Colorado (154)
Connecticut (176)
Europe (74325)
Florida (495)
Georgia (116)
Illinois (306)
Indiana (174)
Maryland (590)
Massachusetts (2656)
Michigan (135)
Minnesota (236)
New Jersey (995)
New York (946)
North Carolina (678)
Northern California (1562)
Ohio (116)
Pennsylvania (811)
South America (1032)
Southern California (1308)
Texas (484)
Washington State (359)
519,765 Results for "symphogen a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
Parkinson’s disease
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
The report comes just two days after Novartis announced its own Parkinson’s drug failure.
December 19, 2024
·
1 min read
·
Annalee Armstrong
CAR-T
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.
December 10, 2024
·
2 min read
·
Tristan Manalac
Drug shortages
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded pharmacies are still making them. That’s unprecedented.
November 26, 2024
·
4 min read
·
Ben Hargreaves
GLP-1
Evidence Mounts for Potential of GLP-1s in Alzheimer’s Disease
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
December 9, 2024
·
6 min read
·
Heather McKenzie
Neurodegenerative disease
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.
November 4, 2024
·
6 min read
·
Heather McKenzie
Drug shortages
FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period
After a couple months of uncertainty, the FDA has told compounding pharmacies that they have 60 to 90 days before the agency will enforce rules to stop their production of GLP-1s.
December 19, 2024
·
3 min read
·
Tristan Manalac
Deals
Servier Completes the Acquisition of Symphogen
Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier’s antibody center of excelle
June 4, 2020
·
2 min read
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
1 of 51,977
Next
